HomeInvestors & MediaNews
- ABL Bio and Lilly enter a multi-program agreement to develop multiple therapeutics across modalities & therapeutic areas utilizing ABL’s Grabody Platform.
Seoul (South Korea) – November 12, 2025, ABL Bio (CEO Sang Hoon Lee), a company specializing in bispecific antibodies, today announced that ABL Bio has entered license, research and collaboration agreement with Eli Lilly and Company (“Lilly”) for the development of therapeutics by utilizing ABL Bio’s Grabody Platform.
ABL Bio and Lilly will collaborate to develop multiple therapeutics across modalities & therapeutic areas utilizing the Grabody Platform.
Under the terms of the agreement, ABL Bio will receive an upfront payment of USD $40 million within 10 days following the completion of the administrative procedures under the Hart–Scott–Rodino Antitrust Improvements Act (HSR Act). In addition to the upfront payment, ABL Bio is eligible to receive up to USD $2.562 billion in development, regulatory, and commercial milestone payments as well as tiered royalties on net sales.
Sang Hoon Lee, CEO of ABL Bio, said “This agreement not only validates the business potential of the Grabody Platform, but also demonstrates the continued expansion of modalities to which Grabody can be applied. We believe Grabody has already established a strong foothold, and we intend to build on this momentum by broadening its indications into therapeutic areas with high unmet medical needs, including obesity and muscle diseases.”
About ABL Bio
ABL Bio is developing various clinical and non-clinical assets based on its bispecific antibody platform ‘Grabody’. Clinical projects for 8 pipelines, including ABL301 (SAR446159), ABL001 (tovecimig), ABL111 (givastomig), ABL503 (ragistomig), ABL105 (YH32367), ABL104 (YH32364), ABL202, and ABL103, are underway for different indications in various countries, including the United States, China, Australia, and Korea. Currently, ABL Bio and Sanofi are in the process of transferring the clinical trial sponsorship of ABL301 (SAR446159) to Sanofi to conduct following clinical studies. ABL001 (tovecimig) has received Fast Track designation by the U.S. Food and Drug Administration (FDA). In addition, ABL111 (givastomig), co-developed with NovaBridge, has presented encouraging data from the Phase 1b clinical trial evaluating the triple combination therapy with nivolumab and chemotherapy in ESMO GI 2025. In addition, ABL Bio is continuously researching and developing several other product candidates, including bispecific antibody-drug conjugates (ADCs).